These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 6135076

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE, Rubens RD.
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [Abstract] [Full Text] [Related]

  • 3. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J, Ratcliffe WA, Howell A, Bundred NJ.
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [Abstract] [Full Text] [Related]

  • 4. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC.
    Br Med J (Clin Res Ed); 1988 Mar 19; 296(6625):811-4. PubMed ID: 3130925
    [Abstract] [Full Text] [Related]

  • 5. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D, Jacquet AF, Burckhardt P.
    Arch Intern Med; 1990 Oct 19; 150(10):2125-8. PubMed ID: 2222097
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.
    Gibbs CJ, Peacock M.
    Postgrad Med J; 1986 Oct 19; 62(732):937-8. PubMed ID: 3774726
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ, Bijvoet OL, Frijlink WB, Sleeboom HP, Mulder H, van Oosterom AT.
    Calcif Tissue Int; 1982 Jul 19; 34(4):321-7. PubMed ID: 6814719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ, Dumon JC.
    Ann Oncol; 1994 Apr 19; 5(4):359-63. PubMed ID: 8075034
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE.
    Am J Med; 1993 Sep 19; 95(3):297-304. PubMed ID: 8368227
    [Abstract] [Full Text] [Related]

  • 17. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
    Gurney H, Grill V, Martin TJ.
    Lancet; 1993 Jun 26; 341(8861):1611-3. PubMed ID: 8099988
    [Abstract] [Full Text] [Related]

  • 18. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D, Portmann L, Jaeger P, Jacquet AF, Burckhardt P.
    Bone; 1986 Jun 26; 7(4):247-53. PubMed ID: 3768203
    [Abstract] [Full Text] [Related]

  • 19. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
    Tan TT, Alzaid AA, Sutcliffe N, Gardner MD, Thomson JA, Boyle IT.
    Postgrad Med J; 1988 Mar 26; 64(749):224-7. PubMed ID: 3174541
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.